Rx Bandz wins Pentagon research contract for battlefield antibiotics

Rx Bandz said Oct. 15 that the U.S. Department of War awarded the company another research and development contract to advance compact auto-injectors for battlefield antibiotic delivery. The deal adds to two existing five-year, $23 million contracts as the company moves toward an FDA device filing by year-end 2026.

Why it matters: - The new contract strengthens Rx Bandz's work with the U.S. military on fast drug delivery in combat settings. - Battlefield infections remain a major risk when wounds are treated late in austere environments. - Rx Bandz's platform is meant to deliver antibiotics at the point of injury or during evacuation, when speed can affect survival.

What happened: - Rx Bandz said Oct. 15 that the U.S. Department of War awarded the company another research and development contract. - The award is a Small Business Innovation Research Phase I contract. - The contract supports work on antibiotics deliverable through Rx Bandz's compact auto-injectors. - The company is based in Denville, New Jersey.

The details: - Rx Bandz's auto-injector platform includes the ultra-compact MiniJect. - The platform can deliver 1 mL to 5 mL of therapeutics. - The range covers small molecules and viscous biologics, including hydrogels. - The Department of War has already contracted with Rx Bandz to develop auto-injectors for ketamine and hydromorphone for pain management, tranexamic acid for hemorrhage control, and epinephrine for shock. - Rx Bandz said it is advancing two five-year, $23 million contracts tied to its auto-injectors. - Jessica Walsh, founder and CEO of Rx Bandz, said the company is developing rugged auto-injectors for military, civilian, EMS, hospital and clinic use. - Half of combat wounds in austere or forward-deployed environments become infected, the company said. - Delayed antibiotic treatment can increase the risk of death from infection and add burden to field medical personnel, the company said. - Rx Bandz said the rapid-response treatment approach could reduce infection rates and improve survivability. - The company is in a Series A equity funding round. - Rx Bandz plans to submit its Device Master File to the FDA by the end of calendar 2026.

Between the lines: - The contract broadens the military relevance of Rx Bandz's delivery platform beyond pain control and hemorrhage management. - The focus on battlefield antibiotics suggests the company is positioning its auto-injectors as a logistics solution as much as a device platform. - The FDA filing target signals a move from development toward commercialization.

What's next: - Rx Bandz will continue work under the new SBIR Phase I contract. - The company will advance its existing five-year contracts and battlefield drug pipeline. - Rx Bandz aims to complete its FDA Device Master File submission by the end of 2026. - The company will use Series A proceeds to support commercial efforts.